All CISA Advisories, EN

Mirion Medical EC2 Software NMIS BioDose

View CSAF

1. EXECUTIVE SUMMARY

  • CVSS v4 8.7
  • ATTENTION: Exploitable remotely/low attack complexity
  • Vendor: Mirion Medical
  • Equipment: EC2 Software NMIS BioDose
  • Vulnerabilities: Incorrect Permission Assignment for Critical Resource, Use of Client-Side Authentication, Use of Hard-coded Credentials

2. RISK EVALUATION

Successful exploitation of these vulnerabilities could allow an attacker to modify program executables, gain access to sensitive information, gain unauthorized access to the application, and execute arbitrary code.

3. TECHNICAL DETAILS

3.1 AFFECTED PRODUCTS

The following Mirion Medical products are affected:

  • EC2 Software NMIS BioDose: Versions prior to 23.0

3.2 VULNERABILITY OVERVIEW

3.2.1 INCORRECT PERMISSION ASSIGNMENT FOR CRITICAL RESOURCE CWE-732

NMIS/BioDose V22.02 and previous versions’ installation directory paths by default have insecure file permissions, which in certain deployment scenarios can enable users on client workstations to modify the program executables and libraries.

CVE-2025-64642 has been assigned to this vulnerability. A CVSS v3.1 base score of 8.0 has been calculated; the CVSS vector string is (AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H).

A CVSS v4 score has also been calculated for CVE-2025-64642. A base score of 7.1 has been calculated; the CVSS vector string is (AV:L/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:H/SC:N/SI:N/SA:N).

3.2.2 […]
Content was cut in order to protect the source.Please visit the source for the rest of the article.

This article has been indexed from All CISA Advisories

Read the original article: